3.31
+0.05(+1.53%)
Currency In USD
| Previous Close | 3.26 |
| Open | 3.24 |
| Day High | 3.36 |
| Day Low | 3.2 |
| 52-Week High | 5.59 |
| 52-Week Low | 2.84 |
| Volume | 329,920 |
| Average Volume | 208,021 |
| Market Cap | 113.83M |
| PE | -2.96 |
| EPS | -1.12 |
| Moving Average 50 Days | 3.79 |
| Moving Average 200 Days | 4.51 |
| Change | 0.05 |
If you invested $1000 in Achieve Life Sciences, Inc. (ACHV) 10 years ago, it would be worth $0.75 as of February 05, 2025 at a share price of $3.31. Whereas If you bought $1000 worth of Achieve Life Sciences, Inc. (ACHV) shares 5 years ago, it would be worth $275.83 as of February 05, 2025 at a share price of $3.31.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Achieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to its Board of Directors
GlobeNewswire Inc.
Jan 10, 2025 1:30 PM GMT
New Directors Bring Extensive Leadership Experience in Corporate Strategy and CommercializationSEATTLE and VANCOUVER, British Columbia, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical compan
Achieve Life Sciences Announces Critical Milestone Successfully Reached in ORCA-OL Cytisinicline Clinical Trial Required for NDA Submission
GlobeNewswire Inc.
Jan 07, 2025 1:30 PM GMT
Over 300 Participants Have Completed Cumulative Six Months of Cytisinicline Treatment in the ORCA-OL Trial, Completing the Long-Term Exposure Requirement for NDA Submission ORCA-OL Long-Term Exposure Timelines Remain on Track with No Safety Concerns
Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week
GlobeNewswire Inc.
Jan 06, 2025 1:30 PM GMT
SEATTLE and VANCOUVER, British Columbia, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company focused on the development and commercialization of cytisinicline for nicotine dependence, an